Tinea pedis (Athlete Foot) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Tinea pedis (Athlete Foot) - Pipeline Review, H1 2018’, provides an overview of the Tinea pedis (Athlete Foot) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot)

- The report reviews pipeline therapeutics for Tinea pedis (Athlete Foot) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Tinea pedis (Athlete Foot) therapeutics and enlists all their major and minor projects

- The report assesses Tinea pedis (Athlete Foot) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tinea pedis (Athlete Foot)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Novan Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Novan Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinea pedis (Athlete Foot) – Overview

Tinea pedis (Athlete Foot) ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinea pedis (Athlete Foot) – Overview

Tinea pedis (Athlete Foot) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Tinea pedis (Athlete Foot) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinea pedis (Athlete Foot) – Companies Involved in Therapeutics Development

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Novan Inc

Tinea pedis (Athlete Foot) – Drug Profiles

AS-2077715 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapaconazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NORS-6491 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinea pedis (Athlete Foot) – Dormant Projects

Tinea pedis (Athlete Foot) – Product Development Milestones

Featured News & Press Releases

May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial

Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Tinea pedis (Athlete Foot), H1 2018

Number of Products under Development by Companies, H1 2018

Products ...

List of Tables

Number of Products under Development for Tinea pedis (Athlete Foot), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Tinea pedis (Athlete Foot) – Pipeline by Astellas Pharma Inc, H1 2018

Tinea pedis (Athlete Foot) – Pipeline by Biolab Farmaceutica Ltda, H1 2018

Tinea pedis (Athlete Foot) – Pipeline by Blueberry Therapeutics Ltd, H1 2018

Tinea pedis (Athlete Foot) – Pipeline by Novan Inc, H1 2018

Tinea pedis (Athlete Foot) – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Tinea pedis (Athlete Foot), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Tinea pedis (Athlete Foot), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports